Cingal™ for Patellofemoral Pain Syndrome

This trial tests Cingal™, a treatment for individuals with patellofemoral pain syndrome, a type of knee pain. Cingal™ combines hyaluronic acid, which lubricates the joint, and a corticosteroid (Triamcinolone Hexacetonide) to reduce inflammation and relieve pain. The trial aims to determine if Cingal™ can improve knee function and provide short-term pain relief. Individuals with persistent knee pain for at least two months, which worsens with activities like squatting or climbing stairs, and who have not found relief from other treatments, might be suitable candidates for this trial.

As an unphased trial, this study provides an opportunity to explore new treatment options for knee pain relief.

The trial protocol does not specify whether you need to stop taking your current medications. However, it mentions that participants should have failed to improve with treatments like NSAIDs (non-steroidal anti-inflammatory drugs), so you might need to discuss your current medications with the trial team.

Research shows that Cingal™, a treatment combining hyaluronic acid and the steroid triamcinolone hexacetonide, is generally safe. Previous studies found that Cingal™ improves knee joint function and reduces pain. Importantly, these trials reported no deaths linked to its use. However, some rare side effects, such as infections or tendon problems, have occurred.

Unlike the standard treatments for patellofemoral pain syndrome, like physical therapy and oral pain relievers, Cingal is administered directly into the knee joint via an ultrasound-guided injection. This precise delivery method ensures that the active ingredients reach the site of pain more effectively. Additionally, Cingal combines a hyaluronic acid with a corticosteroid, triamcinolone hexacetonide, which not only lubricates the joint but also reduces inflammation. Researchers are excited about Cingal because this dual-action approach could provide faster and longer-lasting relief compared to existing options.

Research shows that Cingal™, a treatment combining hyaluronic acid (a joint lubricant) and a corticosteroid, can improve knee movement and reduce pain. In this trial, participants will receive Cingal, which studies have found to result in less pain compared to treatments like Monovisc. Triamcinolone acetonide, one of Cingal's ingredients, significantly lessened knee pain for up to 24 weeks in people with knee problems. Both 10 mg and 40 mg doses of this ingredient effectively reduced knee pain. Overall, these findings suggest that Cingal could ease patellofemoral pain syndrome by reducing pain and improving knee function.³⁴⁶⁷⁸